Core Viewpoint - The acquisition of 100% equity in Changsha Zhongya Medical Imaging Diagnosis Co., Ltd. by Hunan Yimai, a subsidiary of Yimai Sunshine, aims to enhance market position and create synergies in the medical imaging sector in Central China [1][2]. Group 1: Acquisition Details - Yimai Sunshine announced the acquisition of 100% equity in Zhongya Diagnosis for a total price of 29.5 million yuan [1]. - Following the acquisition, Zhongya Diagnosis will become a wholly-owned subsidiary of Hunan Yimai, allowing for the integration of Yimai's product system with Zhongya's business foundation [1][2]. Group 2: Strategic Goals - The acquisition is part of Yimai Sunshine's strategy to leverage its established product offerings and Zhongya's operational strengths to achieve breakthrough performance in the imaging centers [1][2]. - Yimai Sunshine aims to integrate standardized products into existing collaborations with provincial top-tier hospitals, enabling zero customer acquisition costs for revenue generation [2]. Group 3: Company Background and Market Position - Zhongya Diagnosis specializes in early screening and diagnosis of various diseases, including tumors and cardiovascular conditions, and has established long-term partnerships with top hospitals in Hunan [2]. - Yimai Sunshine operates 106 imaging centers across 16 provinces, significantly exceeding competitors in terms of operational scale and regional coverage [3]. Group 4: Management Confidence - The company's management, including the chairman and two executive directors, has committed not to sell shares until December 31, reflecting confidence in the company's future prospects [4].
深耕华中区域协同发展 一脉阳光拟2950万收购众雅诊断